Profile data is unavailable for this security.
About the company
Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates with numerous institutions, such as Karolinska Institutet in Sweden and Dana Farber Cancer Institute, Washington University, Baylor College of Medicine, City of Hope Research & Treatment Center in the Unites States, as well as The International Breast Cancer Study Group (IBCSG) based in Switzerland and Breast International Group in Belgium.
- Revenue in SEK (TTM)7.25m
- Net income in SEK-115.45m
- Incorporated2008
- Employees27.00
- LocationBiovica International ABDag Hammarskjolds vag 54BUppsala Science ParkUPPSALA 752 37SwedenSWE
- Phone+46 184444830
- Fax+46 18572428
- Websitehttps://biovica.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Coegin Pharma AB | 0.00 | -26.00m | 99.97m | 1.00 | -- | 3.81 | -- | -- | -2.25 | -2.25 | 0.00 | 1.06 | 0.00 | -- | -- | -- | -111.12 | -122.02 | -119.99 | -154.70 | -- | -- | -- | -28,466.75 | -- | -55.53 | 0.00 | -- | -- | -- | 20.60 | -- | -- | -- |
| Prolight Diagnostics AB (publ) | 0.00 | -140.00m | 100.40m | 16.00 | -- | 0.5845 | -- | -- | -0.3853 | -0.3853 | 0.00 | 0.2447 | 0.00 | -- | -- | 0.00 | -66.82 | -- | -89.89 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -13.84 | -- |
| AroCell AB (publ) | 51.58m | -50.57m | 103.20m | -- | -- | 0.7926 | -- | 2.00 | -0.2195 | -0.2195 | 0.2239 | 0.5653 | 0.3083 | 6.53 | 5.54 | -- | -30.22 | -29.25 | -32.55 | -31.37 | 12.55 | -9.85 | -98.04 | -231.19 | 4.52 | -- | 0.00 | -- | 16.37 | 122.92 | -0.5494 | -- | -- | -- |
| Kancera AB | 0.00 | -53.07m | 116.58m | 5.00 | -- | 1.40 | -- | -- | -0.5955 | -0.5955 | 0.00 | 0.6849 | 0.00 | -- | -- | 0.00 | -56.73 | -54.82 | -66.40 | -66.21 | -- | 96.28 | -- | -7,249.06 | -- | -- | 0.00 | -- | -- | -- | -23.64 | -- | -- | -- |
| Sprint Bioscience AB | 60.25m | -19.11m | 119.95m | 36.00 | -- | 8.90 | -- | 1.99 | -0.2737 | -0.2737 | 0.863 | 0.1931 | 1.10 | -- | 7.28 | 2,151,857.00 | -34.81 | -71.22 | -82.55 | -113.71 | 58.54 | 62.75 | -31.72 | -110.22 | -- | -- | 0.00 | -- | 60,725.30 | 22.99 | 99.27 | -- | -26.02 | -- |
| Lumito AB (publ) | 17.00k | -31.86m | 128.53m | 13.00 | -- | 1.33 | -- | 7,560.61 | -0.1472 | -0.1472 | 0.00008 | 0.4133 | 0.0001 | -- | 2.43 | 1,133.33 | -26.73 | -20.77 | -30.85 | -22.38 | 42,235.47 | -- | -187,433.80 | -- | 1.10 | -14.60 | 0.1715 | -- | -- | -- | 4.56 | -- | -- | -- |
| NextCell Pharma AB | 10.66m | -41.96m | 131.56m | -- | -- | 1.95 | -- | 12.34 | -0.8805 | -0.8805 | 0.2239 | 0.9249 | 0.1254 | 55.56 | 5.31 | -- | -49.33 | -35.01 | -55.89 | -37.45 | -247.97 | -304.79 | -393.45 | -468.52 | 6.09 | -- | -- | -- | 5.45 | 42.54 | -5.40 | -- | -27.06 | -- |
| AlzeCure Pharma AB | 0.00 | -35.87m | 144.36m | 11.00 | -- | 3.53 | -- | -- | -0.5371 | -0.5371 | 0.00 | 0.4625 | 0.00 | -- | -- | 0.00 | -75.21 | -52.78 | -89.05 | -57.01 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 33.91 | -- | -- | -- |
| Biovica International AB | 7.25m | -115.45m | 151.33m | 27.00 | -- | 1.69 | -- | 20.87 | -1.73 | -1.73 | 0.1055 | 1.06 | 0.0584 | 17.30 | 4.76 | 226,593.80 | -92.98 | -51.94 | -110.37 | -58.18 | -394.72 | -576.01 | -1,592.15 | -2,217.41 | 3.47 | -- | 0.0721 | -- | 115.49 | 19.39 | -12.97 | -- | -54.31 | -- |
| Intervacc AB | 9.78m | -102.66m | 159.05m | 15.00 | -- | 0.785 | -- | 16.26 | -1.36 | -1.36 | 0.1291 | 2.68 | 0.0355 | 3.19 | 1.62 | 651,933.30 | -37.23 | -17.62 | -40.38 | -18.77 | -551.10 | -243.59 | -1,049.76 | -626.90 | 2.90 | -- | 0.0006 | -- | -17.23 | -25.79 | -60.31 | -- | -38.72 | -- |
| Active Biotech AB publ | 0.00 | -41.60m | 178.87m | 8.00 | -- | 94.32 | -- | -- | -0.0644 | -0.0644 | 0.00 | 0.0018 | 0.00 | -- | -- | -- | -284.93 | -57.97 | -1,027.16 | -97.83 | -- | -- | -- | -1,454.61 | -- | -- | 0.5758 | -- | -- | -- | 21.54 | -- | -- | -- |
| Biosergen AB | 0.00 | -26.60m | 180.41m | 2.00 | -- | 11.67 | -- | -- | -0.286 | -0.286 | 0.00 | 0.0557 | 0.00 | -- | -- | 0.00 | -145.58 | -- | -216.30 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 32.25 | -- | -- | -- |
| Exact Therapeutics AS | 0.00 | -53.98m | 183.16m | 12.00 | -- | 10.67 | -- | -- | -1.66 | -1.66 | 0.00 | 0.5435 | 0.00 | -- | -- | -- | -130.29 | -40.21 | -170.98 | -45.67 | -- | -- | -- | -- | -- | -- | 0.0502 | -- | -- | -- | -20.52 | -- | -- | -- |
| Xintela AB | 381.00k | -40.83m | 192.24m | -- | -- | -- | -- | 504.57 | -0.0817 | -0.0817 | 0.0008 | -0.0319 | 0.0306 | -- | 0.0493 | -- | -327.65 | -181.06 | -- | -391.61 | 100.00 | -- | -10,717.06 | -235,894.00 | -- | -203.91 | -- | -- | -- | -45.54 | 18.32 | -- | -61.47 | -- |
| Acousort AB | 3.44m | -19.30m | 200.12m | -- | -- | 13.08 | -- | 58.19 | -1.33 | -1.33 | 0.2379 | 1.02 | 0.1461 | 4.08 | 1.96 | -- | -81.99 | -48.62 | -137.70 | -69.77 | -159.41 | -68.05 | -561.21 | -299.58 | 1.91 | -- | 0.00 | -- | 11.51 | 38.81 | -24.01 | -- | -- | -- |
| SenzaGen AB | 55.29m | -20.60m | 210.95m | 32.00 | -- | 2.30 | -- | 3.82 | -0.8299 | -0.8299 | 2.23 | 3.11 | 0.5019 | 3.32 | 5.80 | 1,626,029.00 | -18.70 | -25.84 | -23.34 | -29.85 | 71.63 | 68.62 | -37.27 | -132.29 | 2.76 | -51.34 | 0.0443 | -- | 19.39 | 90.32 | 11.30 | -- | -21.10 | -- |
Data as of Nov 13 2024. Currency figures normalised to Biovica International AB's reporting currency: Swedish Krona SEK
0.33%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Deka Investment GmbHas of 31 Mar 2024 | 264.16k | 0.31% |
| FCG Fonder ABas of 30 Sep 2024 | 15.69k | 0.02% |
Data from 30 Sep 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
